Breaking News, Collaborations & Alliances

uBriGene Acquires Mustang Bio’s GMP Manufacturing Facility

Location will produce cell and gene therapies and provide contract analytical services.

uBriGene, a cell and gene therapy contract development and manufacturing organization (CDMO), is expanding into the U.S. market with the acquisition of a state-of-the-art GMP manufacturing facility from NASDAQ-listed company Mustang Bio, Inc. The cell and gene therapy (CGT) CDMO has an established global footprint with two GMP manufacturing facilities in China and its headquarters in Vancouver, Canada. The latest move will see uBriGene expand its global headcount to over 500 employees. The...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters